Approval

Approval  ·  Weekly Digest - 18 October to 24 October 2025
Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma

Weekly Digest – October 2025 Weekly Digest – October 2025 23 October 2025: Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma The US FDA has approved Blenrep (Belantamab mafodotin) in combination with bortezomib and dexamethasone […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 18 October to 24 October 2025
Core product Trastuzumab botidotin approved for marketing by the NMPA for 2L+ HER2+ breast cancer

Weekly Digest – October 2025 Weekly Digest – October 2025 17 October 2025: Core product Trastuzumab botidotin approved for marketing by the NMPA for 2L+ HER2+ breast cancer Sichuan Kelun-Biotech’s core product trastuzumab botidotin (A166) received marketing approval from China’s […]

by Sandhya Ramalingam

Continue Reading